Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
Current Signal: SELL (auto-tracking)
0.48% $18.55
America/New_York / 28 mar 2024 @ 09:40
FUNDAMENTALS | |
---|---|
MarketCap: | 840.32 mill |
EPS: | -1.520 |
P/E: | -12.20 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 45.30 mill |
Avg Daily Volume: | 0.416 mill |
RATING 2024-03-27 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -12.20 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.37x |
Company: PE -12.20 | industry: PE 33.06 |
DISCOUNTED CASH FLOW VALUE |
---|
$-12.04 (-164.88%) $-30.59 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 17.46 - 19.64 ( +/- 5.85%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-21 | Wichterman Troy | Sell | 520 | Common Stock |
2024-03-08 | Duross Amy | Buy | 11 264 | Common Stock |
2024-03-12 | Duross Amy | Sell | 6 135 | Common Stock |
2024-03-13 | Duross Amy | Sell | 5 065 | Common Stock |
2024-03-08 | Richardson Garrie | Buy | 12 516 | Common Stock |
INSIDER POWER |
---|
83.30 |
Last 100 transactions |
Buy: 2 104 632 | Sell: 181 819 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $18.55 (0.48% ) |
Volume | 0.0024 mill |
Avg. Vol. | 0.416 mill |
% of Avg. Vol | 0.585 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $18.50 | N/A | Active |
---|
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.